Abstract
Glomerular diseases are a leading cause of morbidity and mortality worldwide and are characterized by proteinuria, a strong predictor of disease progression and end-stage kidney disease. Currently, there are limited therapies and despite the recent approval of sodium glucose co-transporter 2 inhibitors (SGLT2i), residual risk remains. It is known that endothelin A (ETA) receptor activation drives glomerular injury, inflammation, and fibrosis through a common pathogenic pathway. Atrasentan, a potent and selective ETA receptor antagonist that has shown clinically significant reduction in proteinuria and risk of kidney failure in a study of over 5,300 patients with diabetic kidney disease (DKD), represents a promising therapy to reduce proteinuria and preserve kidney function in proteinuric glomerular diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
